Abstract: A method of performing personalized neuromodulation on a subject is provided. The method includes acquiring functional magnetic resonance imaging (fMRI) data of a brain of the subject. The method also includes calculating functional connectivity of the brain between a voxel in a subcortical region of the brain and a voxel in a cortical region of the brain, based on the fMRI data. The method also includes identifying a target location in the brain to be targeted by neuromodulation based on the calculated functional connectivity.

Abstract: A system comprising a hosting service configured to perform: providing, to a trusted entity on a central processing unit, a command for a launch of a virtual machine (VM); assigning, to the VM, at least a portion of memory for the guest operating system; submitting, to the trusted entity, a request to measure an address space of the VM to provide a measurement digest of the address space of the guest operating system; including, in a configuration object, a policy provided by the user for the service logic, wherein the policy defines one or more rules for the service logic, wherein the one or more rules include at least one rule for which containers may run in the guest operating system; hashing the policy to provide a hash digest of the policy; submitting, to the trusted entity, the hash digest of the policy; and completing the launch of the VM.

Abstract: A system comprising a hosting service configured to perform: providing, to a trusted entity on a central processing unit, a command for a launch of a virtual machine (VM); assigning, to the VM, at least a portion of memory for the guest operating system; submitting, to the trusted entity, a request to measure an address space of the VM to provide a measurement digest of the address space of the guest operating system; including, in a configuration object, a policy provided by the user for the service logic, wherein the policy defines one or more rules for the service logic, wherein the one or more rules include at least one rule for which containers may run in the guest operating system; hashing the policy to provide a hash digest of the policy; submitting, to the trusted entity, the hash digest of the policy; and completing the launch of the VM.

Abstract: A processing system comprising one or more chips, each comprising a plurality of tiles is described. Each tile comprises a respective processing unit and memory, the memory storing a codelet. The processing system has at least one encryption unit configured to encrypt and decrypt data transferred between the tiles and a trusted computing entity via an external computing device. The codelets are configured to instruct the tiles to transfer the encrypted data by reading from and writing to a plurality of memory regions at the external memory such that a plurality of streams of encrypted data are formed, each stream using an individual one of the memory regions at the external computing device.

Abstract: A utility shelf mounted inside the cargo area of a pickup truck equipped with a camper shell. The utility shelf spans across the width of the camper shell resting on the base mounting flanges of the camper shell. The utility shelf has a flat rectangular shelf panel with forward and aft support rails to support objects being transported. Shelf panels are mounted low on the support rails creating a raised edge to keep items in place. Support rails and shelf panel are hinged at midpoint thereby allowing utility shelf to be lifted in the center to fold in half for removal and stowage. Each support rail hinge incorporates a concealed stop to keep the shelf flat when deployed. Support rail hinges are designed to reduce the possibility of pinched fingers while deploying. The ends of each support rail incorporate a tool free adjustable extender to allow for proper fit.

Abstract: A utility shelf mounted inside the cargo area of a pickup truck equipped with a camper shell. The utility shelf spans across the width of the camper shell resting on the base mounting flanges of the camper shell. The utility shelf has a flat rectangular shelf panel with forward and aft support rails to support objects being transported. Shelf panels are mounted low on the support rails creating a raised edge to keep items in place. Support rails and shelf panel are hinged at midpoint thereby allowing utility shelf to be lifted in the center to fold in half for removal and stowage. Each support rail hinge incorporates a concealed stop to keep the shelf flat when deployed. Support rail hinges are designed to reduce the possibility of pinched fingers while deploying. The ends of each support rail incorporate a tool free adjustable extender to allow for proper fit.

Abstract: Inhibitors of sodium glucose cotransporter 1 (SGLT1), compositions comprising them, and methods of their use to treat diseases and disorders such as diabetes are disclosed. Particular compounds are of the formula: the various substituents of which are defined herein.

Abstract: Inhibitors of sodium glucose cotransporter 1 (SGLT1), compositions comprising them, and methods of their use to treat diseases and disorders such as diabetes are disclosed. Particular compounds are of the formula: the various substituents of which are defined herein.

Abstract: Inhibitors of sodium glucose cotransporter 1 (SGLT1), compositions comprising them, and methods of their use to treat diseases and disorders such as diabetes are disclosed. Particular compounds are of the formula: the various substituents of which are defined herein.

Abstract: Pyrazolo[1,5-a]pyrimidine-based compounds of the formula: are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by mediated by adaptor associated kinase 1 activity are also disclosed.

Abstract: Compounds that may be used to inhibit Notum Pectinacetylesterase are described, as well as compositions comprising them, and methods of their use to treat diseases and disorders affecting bone.

Abstract: Imidazo[1,2-b]pyridazine-based compounds of the formula: are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by mediated by adaptor associated kinase 1 activity are also disclosed.

Abstract: Inhibitors of sodium glucose cotransporter 1 (SGLT1), compositions comprising them, and methods of their use to treat diseases and disorders such as diabetes are disclosed. Particular compounds are of the formula: the various substituents of which are defined herein.

Abstract: Pyrazolo[1,5-a]pyrimidine-based compounds of the formula: are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by adaptor associated kinase 1 activity are also disclosed.

Abstract: Imidazo[1,2-b]pyridazine-based compounds of the formula: are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by mediated by adaptor associated kinase 1 activity are also disclosed.

Abstract: Inhibitors of sodium glucose cotransporter 1 (SGLT1), compositions comprising them, and methods of their use to treat diseases and disorders such as diabetes are disclosed. Particular compounds are of the formula: the various substituents of which are defined herein.

Abstract: Pyrazolo[1,5-a]pyrimidine-based compounds of the formula: are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by mediated by adaptor associated kinase 1 activity are also disclosed.

Abstract: Imidazo[1,2-b]pyridazine-based compounds of the formula: are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by mediated by adaptor associated kinase 1 activity are also disclosed.

Abstract: Pyrazolo[1,5-a]pyrimidine-based compounds of the formula: are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by adaptor associated kinase 1 activity are also disclosed.

Abstract: Inhibitors of sodium glucose cotransporter 1 (SGLT1), compositions comprising them, and methods of their use to treat diseases and disorders such as diabetes are disclosed. Particular compounds are of the formula: the various substituents of which are defined herein.